A Phase 1, Double-Blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in Systemic Lupus Erythematosus.

Trial Profile

A Phase 1, Double-Blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in Systemic Lupus Erythematosus.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs MEDI 570 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 06 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Planned number of patients changed from 50 to 46 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top